Regado Biosciences Priced, Nasdaq: RGDO
Developing break-through anticoagulant system for cardiovascular surgeries.
Industry: Health Care
First Day Return: +17.5%
RGDO
Developing break-through anticoagulant system for cardiovascular surgeries.
| IPO Data | |
|---|---|
| IPO Date | 08/21/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $43 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Basking Ridge, NJ, United States |
| Founded | 2001 |
| Employees at IPO | 30 |
| Website www.regadobio.com | |
IPO News for Regado Biosciences
Regado Biosciences (RGDO) Performance
